🧫

Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in AD

active
experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-caar-t-c
🧫 Experiment Protocol Clinicalproposed
SUMMARY
# Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in AD ## Background and Rationale Alzheimer's disease (AD) is characterized by progressive neurodegeneration, with emerging evidence suggesting that autoantibodies targeting neuronal antigens contribute to disease pathology beyond amyloid-beta accumulation. Pathogenic autoantibodies against BACE1, AQP4, and various neuronal surface proteins have been detected in AD patients and correlate with cognitive decline and synapt
METHODOLOGY NOTES
Phase I: Screening and enrollment of 24 mild-to-moderate AD patients (MMSE 18-26) with confirmed serum levels of anti-BACE1, anti-AQP4, or anti-neuronal autoantibodies ≥2-fold above healthy controls. Patients undergo comprehensive baseline assessments including neuropsychological testing, MRI, CSF collection, and immune profiling. Phase II: CAAR-T cell manufacturing involves leukapheresis followed by T cell isolation, transduction with lentiviral vectors encoding target-specific CAARs, and ex vivo expansion for 10-14 days with quality control testing. Phase III: Dose escalation using 3+3 design with three cohorts receiving 1×10^6, 3×10^6, or 1×10^7 CAAR-T cells/kg via intravenous infusion following lymphodepleting chemotherapy (fludarabine 25mg/m² and cyclophosphamide 250mg/m² for 3 days). Phase IV: Intensive safety monitoring for 28 days including daily vital signs, cytokine release syndrome assessment, and neurological evaluations. Phase V: Long-term follow-up for 12 months with mont
Metadatasource: {'type': 'manual', 'source_name': 'wiki'
source{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.898370Z'}
summary# Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in AD ## Background and Rationale Alzheimer's disease (AD) is characterized by progressive neurodegeneration, with emerging
entities{'genes': ['CAAR'], 'diseases': ["Alzheimer's Disease"]}
model_systemhuman
_schema_version1
experiment_typeclinical
primary_outcomeValidate Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in AD
methodology_notesPhase I: Screening and enrollment of 24 mild-to-moderate AD patients (MMSE 18-26) with confirmed serum levels of anti-BACE1, anti-AQP4, or anti-neuronal autoantibodies ≥2-fold above healthy controls.
replication_statussingle_study
extraction_metadata{'backfill_at': '2026-04-16T01:00:16.898375', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}
📊 Evidence Profile Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
474
Outgoing
465
0 supporting 0 contradicting 0 neutral
View full evidence profile →
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.